In Review: Senate Bill 173, restricting specialty drug designations, failed to advance through the Senate Committee on Appropriations. The bill is no longer eligible for consideration this session. PCMA will continue to monitor alternative vehicles for specialty drug language.
If you have any questions, please contact Phil Christofanelli at pchristofanelli@pcmanet.org.
